http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016021551-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33ee5af693d9d4020bfd5546e843e0f1
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-0092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2090-378
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B18-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51
filingDate 2015-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82ce6601e39e4c3268e03f51e5dcc4be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95e8869a9b1c896102f723801ca1dc99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22cfc4ba73081bdc40c2d0d5e3faca2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f86db7271d368550c289cc838d38e6d2
publicationDate 2016-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2016021551-A1
titleOfInvention Anti-cancer agent for use in combination therapy of high intensity focused ultrasound therapy and anti-cancer agent therapy
abstract The present invention provides a cancer therapy method having reduced adverse side effects. Specifically, an anti-cancer agent comprising an anthracycline is used in such a manner that the anthracycline can be administered to a cancer patient at a dose of 0.5 to 7.5 mg/kg body weight in a combination therapy of a high intensity focused ultrasound therapy at a radiation intensity of 320 to 700 W/cm2 and an anti-cancer agent therapy.
priorityDate 2014-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2000237199-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3763
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504051
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507060
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504230
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1950
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451030023
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41867
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65348
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1950

Total number of triples: 35.